{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:21:50Z","timestamp":1788906110230,"version":"build-2803163510"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T00:00:00Z","timestamp":1601856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.560888","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T17:55:10Z","timestamp":1601920510000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Identification of Ovarian Cancer Patients Most Likely to Achieve Chemotherapy Response Score 3 Following Neoadjuvant Chemotherapy: Development of a Predictive Nomogram"],"prefix":"10.3389","volume":"10","author":[{"given":"Wei-feng","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"B1","volume-title":"American Cancer Society. Cancer Facts and Figures 2017","author":"Alteri","year":"2017"},{"key":"B2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","article-title":"NCCN guidelines insights: Ovarian cancer, version 1.2019","volume":"17","author":"Armstrong","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143","author":"Berek","year":"2018","journal-title":"Int J Gynaecol Obstet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ygyno.2016.12.020","article-title":"Neoadjuvant chemotherapy for newly diagnosed ovarian cancer: it's all about selection","volume":"144","author":"Dizon","year":"2017","journal-title":"Gynecol Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e4797","DOI":"10.1097\/MD.0000000000004797","article-title":"Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer","volume":"95","author":"Luo","year":"2016","journal-title":"Medicine."},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ygyno.2013.01.009","article-title":"Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma","volume":"129","author":"Rauh-Hain","year":"2013","journal-title":"Gynecol Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ygyno.2016.01.008","article-title":"Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center","volume":"140","author":"Mueller","year":"2016","journal-title":"Gynecol Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3389\/fonc.2019.00778","article-title":"Pathological chemotherapy response score in patients affected by high grade serous ovarian carcinoma: the prognostic role of omental and ovarian residual disease","volume":"9","author":"Santoro","year":"2019","journal-title":"Front Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ygyno.2019.04.679","article-title":"Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: a systematic review and meta-analysis of individual patient data","volume":"154","author":"Cohen","year":"2019","journal-title":"Gynecol Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.ygyno.2018.08.042","article-title":"Prognostic implications of histological tumor regression (Bohm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma","volume":"151","author":"Rajkumar","year":"2018","journal-title":"Gynecol Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/ijgc-2019-000561","article-title":"External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response","volume":"30","author":"Zorzato","year":"2020","journal-title":"Int J Gynecol Cancer."},{"key":"B14","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/his.13399","article-title":"The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma","volume":"72","author":"Singh","year":"2018","journal-title":"Histopathology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","article-title":"Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the international collaboration on cancer reporting (ICCR)","volume":"28","author":"McCluggage","year":"2015","journal-title":"Mod Pathol."},{"key":"B17","first-page":"1865","article-title":"Dynamic analysis of CA125 decline during neoadjuvant chemotherapy in patients with epithelial ovarian cancer as a predictor for platinum sensitivity","volume":"36","author":"Pelissier","year":"2016","journal-title":"Anticancer Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1097\/IGC.0b013e31821ce903","article-title":"Possible use of CA-125 level normalization after the third chemotherapy cycle in deciding on chemotherapy regimen in patients with epithelial ovarian cancer: brief report","volume":"21","author":"Skaznik-Wikiel","year":"2011","journal-title":"Int J Gynecol Cancer."},{"key":"B19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1701-2163(16)32914-0","article-title":"Importance of CA125 normalization during neoadjuvant chemotherapy followed by planned delayed surgical debulking in patients with epithelial ovarian cancer","volume":"30","author":"Le","year":"2008","journal-title":"J Obstet Gynaecol Can."},{"key":"B20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13048-016-0270-7","article-title":"Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer","volume":"9","author":"Pelissier","year":"2016","journal-title":"J Ovarian Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"12389","DOI":"10.1007\/s13277-014-2553-1","article-title":"Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer","volume":"35","author":"Vallius","year":"2014","journal-title":"Tumour Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1634\/theoncologist.2010-0236","article-title":"The prognostic impact of duration of anemia during chemotherapy in advanced epithelial ovarian cancer","volume":"16","author":"Kim","year":"2011","journal-title":"Oncologist."},{"key":"B23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet."},{"key":"B25","doi-asserted-by":"publisher","first-page":"5516","DOI":"10.1200\/JCO.2018.36.15_suppl.5516","article-title":"Survival analyses from a randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer with high tumor load (SCORPION trial)","volume":"36","author":"Fagotti","year":"2018","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: society of gynecologic oncology and American society of clinical oncology clinical practice guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J Clin Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejca.2020.02.020","article-title":"Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III\/IV ovarian, tubal and peritoneal cancers in phase III randomised trial","volume":"130","author":"Onda","year":"2020","journal-title":"Eur J Cancer."},{"key":"B28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","article-title":"Can advanced-stage ovarian cancer be cured?","volume":"13","author":"Narod","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ygyno.2014.01.028","article-title":"TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer","volume":"132","author":"Zhang","year":"2014","journal-title":"Gynecol Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ygyno.2014.09.005","article-title":"CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy","volume":"135","author":"Pelissier","year":"2014","journal-title":"Gynecol Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.7150\/jca.16761","article-title":"Reduction of CA125 levels during neoadjuvant chemotherapy can predict cytoreduction to no visible residual disease in patients with advanced epithelial ovarian cancer, primary carcinoma of fallopian tube and peritoneal carcinoma","volume":"7","author":"Zeng","year":"2016","journal-title":"J Cancer."},{"key":"B33","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/IGC.0000000000000944","article-title":"The role of he4, a novel biomarker, in predicting optimal cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer","volume":"27","author":"Plotti","year":"2017","journal-title":"Int J Gynecol Cancer."},{"key":"B35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ygyno.2018.09.001","article-title":"Genomics to immunotherapy of ovarian clear cell carcinoma: UNIQUE opportunities for management","volume":"151","author":"Oda","year":"2018","journal-title":"Gynecol Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00066-006-1543-7","article-title":"Impact of hemoglobin levels on tumor oxygenation: the higher, the better?","volume":"182","author":"Vaupel","year":"2006","journal-title":"Strahlenther Onkol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"790","DOI":"10.2174\/187152008785914798","article-title":"Tumour hypoxia affects the responsiveness of cancer cells to chemotherapy and promotes cancer progression","volume":"8","author":"Cosse","year":"2008","journal-title":"Anticancer Agents Med Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1634\/theoncologist.9-90005-31","article-title":"Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?","volume":"9","author":"Harrison","year":"2004","journal-title":"Oncologist."},{"key":"B39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ygyno.2018.08.009","article-title":"Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery","volume":"151","author":"Son","year":"2018","journal-title":"Gynecol Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","article-title":"Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis","volume":"130","author":"Chang","year":"2013","journal-title":"Gynecol Oncol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.560888\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T17:55:13Z","timestamp":1601920513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.560888\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":40,"alternative-id":["10.3389\/fonc.2020.560888"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.560888","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,5]]},"article-number":"560888"}}